Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hazel Sutherland

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Metabolites|June 23, 2022
Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of AlkaptonuriaAndrew S Davison, Brendan P Norman, Hazel Sutherland, et al.
American Journal of Physiology. Cell Physiology|October 21, 2025
Dynamic time course of muscle proteome adaptation to programmed resistance training in ratsConnor A Stead, Stuart J Hesketh, Aaron C Q Thomas, et al.
JIMD Reports|May 6, 2015
Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric MiceCraig M Keenan, Andrew J Preston, Hazel Sutherland, et al.
Calcified Tissue International|October 15, 2020
Anatomical Distribution of Ochronotic Pigment in Alkaptonuric Mice is Associated with Calcified Cartilage Chondrocytes at Osteochondral InterfacesJuliette H Hughes, Craig M Keenan, Hazel Sutherland, et al.
Annals of the Rheumatic Diseases|March 21, 2013
Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinoneAndrew J Preston, Craig M Keenan, Hazel Sutherland, et al.
Human Molecular Genetics|May 25, 2026
Specific knockout of kidney homogentisate 1,2-dioxygenase reveals that local metabolism of tyrosine and homogentisic acid is negligible in alkaptonuriaDominic A Rutland, Brendan P Norman, Juliette H Hughes, et al.
Clinical Chemistry|February 21, 2019
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to AlkaptonuriaBrendan P Norman, Andrew S Davison, Gordon A Ross, et al.
Journal of Inherited Metabolic Disease|September 11, 2019
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuriaJuliette H Hughes, Peter J M Wilson, Hazel Sutherland, et al.
Human Molecular Genetics|October 11, 2019
Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuriaJuliette H Hughes, Ke Liu, Antonius Plagge, et al.
Metabolites|October 27, 2022
Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated AlkaptonuriaBrendan P Norman, Andrew S Davison, Bryony Hickton, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Metabolites|June 23, 2022
Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of AlkaptonuriaAndrew S Davison, Brendan P Norman, Hazel Sutherland, et al.
American Journal of Physiology. Cell Physiology|October 21, 2025
Dynamic time course of muscle proteome adaptation to programmed resistance training in ratsConnor A Stead, Stuart J Hesketh, Aaron C Q Thomas, et al.
JIMD Reports|May 6, 2015
Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric MiceCraig M Keenan, Andrew J Preston, Hazel Sutherland, et al.
Calcified Tissue International|October 15, 2020
Anatomical Distribution of Ochronotic Pigment in Alkaptonuric Mice is Associated with Calcified Cartilage Chondrocytes at Osteochondral InterfacesJuliette H Hughes, Craig M Keenan, Hazel Sutherland, et al.
Annals of the Rheumatic Diseases|March 21, 2013
Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinoneAndrew J Preston, Craig M Keenan, Hazel Sutherland, et al.
Human Molecular Genetics|May 25, 2026
Specific knockout of kidney homogentisate 1,2-dioxygenase reveals that local metabolism of tyrosine and homogentisic acid is negligible in alkaptonuriaDominic A Rutland, Brendan P Norman, Juliette H Hughes, et al.
Clinical Chemistry|February 21, 2019
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to AlkaptonuriaBrendan P Norman, Andrew S Davison, Gordon A Ross, et al.
Journal of Inherited Metabolic Disease|September 11, 2019
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuriaJuliette H Hughes, Peter J M Wilson, Hazel Sutherland, et al.
Human Molecular Genetics|October 11, 2019
Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuriaJuliette H Hughes, Ke Liu, Antonius Plagge, et al.
Metabolites|October 27, 2022
Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated AlkaptonuriaBrendan P Norman, Andrew S Davison, Bryony Hickton, et al.
Pageof 4